https://www.thepeptidenewsroom.com/three-dietitians-go-public-on-their-own-glp-1-use-and-the-stigma-that-followed/ The Peptide Newsroom en 2026-09-04 Three Dietitians Go Public on Their Own GLP-1 Use, and the Stigma That Followed https://www.thepeptidenewsroom.com/retatrutide-is-still-in-trials-but-the-import-data-says-it-is-already-here/ The Peptide Newsroom en 2026-09-04 Retatrutide Is Still in Trials, But the Import Data Says It Is Already Here https://www.thepeptidenewsroom.com/fda-tracking-hundreds-of-reports-on-compounded-weight-loss-drugs-and-unapproved-/ The Peptide Newsroom en 2026-09-04 FDA Tracking Hundreds of Reports on Compounded Weight-Loss Drugs and Unapproved Peptides https://www.thepeptidenewsroom.com/copper-peptides-go-mainstream-but-the-ghk-cu-evidence-is-thinner-than-the-market/ The Peptide Newsroom en 2026-09-04 Copper Peptides Go Mainstream, But the GHK-Cu Evidence Is Thinner Than the Marketing https://www.thepeptidenewsroom.com/tirzepatide-research-digest-what-surpass-cvot-measured-and-what-it-left-open/ The Peptide Newsroom en 2026-09-03 Tirzepatide Research Digest: What SURPASS-CVOT Measured, and What It Left Open https://www.thepeptidenewsroom.com/ten-vendors-certificates-of-analysis-ranked-on-documentation-alone/ The Peptide Newsroom en 2026-09-03 Ten Vendors' Certificates of Analysis, Ranked on Documentation Alone https://www.thepeptidenewsroom.com/paid-advertorial-pitches-10-ghk-cu-serum-but-the-full-ingredient-list-isnt-publi/ The Peptide Newsroom en 2026-09-03 Paid Advertorial Pitches 10% GHK-Cu Serum, But the Full Ingredient List Isn't Published https://www.thepeptidenewsroom.com/glp-1s-quiet-food-noise-but-eating-disorder-clinicians-say-the-signal-may-matter/ The Peptide Newsroom en 2026-09-03 GLP-1s Quiet Food Noise, But Eating Disorder Clinicians Say the Signal May Matter https://www.thepeptidenewsroom.com/fda-sends-five-warning-letters-to-peptide-sellers-over-unapproved-weight-loss-co/ The Peptide Newsroom en 2026-09-03 FDA Sends Five Warning Letters to Peptide Sellers Over Unapproved Weight-Loss Copies https://www.thepeptidenewsroom.com/fda-approves-mounjaro-for-cardiovascular-risk-reduction-but-the-trial-population/ The Peptide Newsroom en 2026-09-03 FDA Approves Mounjaro for Cardiovascular Risk Reduction, But the Trial Population Was Narrow